1. Home
  2. GD vs VRTX Comparison

GD vs VRTX Comparison

Compare GD & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo General Dynamics Corporation

GD

General Dynamics Corporation

HOLD

Current Price

$341.60

Market Cap

86.9B

Sector

Industrials

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$431.24

Market Cap

96.6B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
GD
VRTX
Founded
2019
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Marine Transportation
EDP Services
Sector
Industrials
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
86.9B
96.6B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
GD
VRTX
Price
$341.60
$431.24
Analyst Decision
Buy
Buy
Analyst Count
18
26
Target Price
$342.41
$489.17
AVG Volume (30 Days)
1.1M
1.5M
Earning Date
10-24-2025
11-03-2025
Dividend Yield
1.76%
N/A
EPS Growth
17.69
N/A
EPS
15.44
14.22
Revenue
$51,509,000,000.00
$11,723,300,000.00
Revenue This Year
$12.01
$10.95
Revenue Next Year
$4.48
$9.55
P/E Ratio
$22.13
$30.49
Revenue Growth
11.86
10.33
52 Week Low
$239.20
$362.50
52 Week High
$360.50
$519.68

Technical Indicators

Market Signals
Indicator
GD
VRTX
Relative Strength Index (RSI) 50.07 55.18
Support Level $334.35 $418.53
Resistance Level $343.06 $435.85
Average True Range (ATR) 5.66 9.82
MACD -0.87 -0.47
Stochastic Oscillator 37.39 65.37

Price Performance

Historical Comparison
GD
VRTX

About GD General Dynamics Corporation

General Dynamics is a defense contractor and business jet manufacturer. The firm's segments are aerospace, marine, combat systems, and technologies. General Dynamics' aerospace segment manufactures Gulfstream business jets and operates a global aircraft servicing operation. Combat systems produces land-based combat vehicles such as the M1 Abrams tank and Stryker armored personnel carrier, as well as munitions. The marine segment builds and services nuclear-powered submarines, destroyers, and Navy support ships. The technologies segment contains two main units: an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computing, intelligence, surveillance, and reconnaissance capabilities to the military.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: